On Oct. 23, 2020, Entos Pharmaceuticals announced it was receiving advisory services and funding of up to $5 million from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) as part of the Government of Canadaﾒs continuing support for the development of domestic COVID-19 vaccine candidates.

Entos developed a Fusogenix DNA vaccine called Covigenix, that in preclinical studies, induced a strong neutralizing antibody response plus a potent and balanced T cell response against SARS-CoV-2, the virus that causes COVID-19.